cymabay therapeutics stock

Free forex prices, toplists, indices and lots more. 10:08AM : Acuity Brands and Ushio Partner for Care222 UV Light Module. The stock has a consensus analyst rating of "Buy." CYMABAY THERAPEUTICS, INC. (CBAY) CymaBay Therapeutics, Inc.is a clinical-stage biopharmaceutical company. View the latest CBAY stock quote and chart on MSN Money. Company Summary. CYMABAY ALERT: Bragar Eagel & Squire, P.C. Valuation & Earnings Cymabay Therapeutics Inc () Stock Market info Recommendations: Buy or sell Cymabay Therapeutics stock? ET on SmarterAnalyst Pacira (PCRX) Gets … 4.0% of CymaBay Therapeutics shares are owned by company insiders. On August 18, 2021 "B. Riley" gave "$13.00 - $10.00" rating for CBAY. The first book to cover the groundbreaking development and clinical applications of Magnetic Resonance Elastography, this book is essential for all practitioners interested in this revolutionary diagnostic modality. CBAY 3.89 0.02 (0.51%) Post-Market 0.09 (2.31%) 8,166. The company was founded on October 5, 1988 and is headquartered in Newark, CA. Get the FREE 14-day TRIAL SUBSCRIPTION with no further commitment. CymaBay Therapeutics To Report Third Quarter 2020 Financial Results On Thursday, November 5, 2020. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 167 thousand more shares were traded than the day before. View real-time stock prices and stock quotes for a full financial overview. Visit Cymabay Therapeuticss profile for more information. Customizable interactive chart for Cymabay Therapeutics with latest real-time price quote, charts, latest news, technical analysis and opinions. Zacks. Our recommended stop-loss: 4.0% of CymaBay Therapeutics shares are owned by company insiders. Get the latest Teva Pharmaceutical Industries Ltd. TEVA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. These are high morbidity and mortality with an overall poor result from treatment. Why is it that hepatobiliary cancer carries with it such a dismal prognosis? First of all, these diseases present, for the most part, in an advanced state. Something went wrong while loading Watchlist. Top hedge fund managers use TOGGLE. The division of the book into these sections reflects the biological and clinical differences between these tumor types and will permit the authors to address the diagnostic, interventional or treatment issues specific to each tumor type. Energy Focus Announces 1-for-5 Reverse Stock Split. Found inside – Page 1If you're specialising in allergy and immunology and require concise, practical and clinical guidance from one of the world's leading institutions in this field, then this is the perfect book for you. ... (ACHV) and CymaBay Therapeutics (CBAY) May. Technical Analysis of CymaBay Therapeutics Inc. (NASDAQ:CBAY) stock To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. Real-time data provided for free by IEX. This text and CD package covers all major advances in the field of endoscopic and laparoscopic surgery. In this book, Susanne Trimbath gives a sobering account of naked short selling, the failure to settle, and her efforts over decades, trying to get this fixed. See today’s analyst top recommended stocks >> Create a list of the investments you want to track. The Cymabay Therapeutics probability density function shows the probability of Cymabay Therapeutics stock to fall within a particular range of prices over 90 days. The Cymabay Therapeutics Inc stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. CymaBay Therapeutics Inc (NASDAQ:CBAY) was in 18 hedge funds’ portfolios at the end of March. CBAY updated stock price target summary. CYMABAY THERAPEUTICS. In total, 378 thousand shares were bought and sold for approximately $1.49 million. Shares of CymaBay Therapeutics (NASDAQ:CBAY) jumped 109% last month, according to data from S&P Global Market Intelligence. Latest Share Price and Events Stable Share Price : CBAY is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week. CymaBay Therapeutics stock price target raised to $6.00 from $1.50 at B. Riley FBR MarketWatch. Enabling power: European Union (Withdrawal) Act 2018, s. 8 (1). CymaBay Therapeutics Inc. is a biopharmaceutical company. Support: $3.93. In the past three months, Aptose Biosciences insiders have sold 21.68% more of their company's stock than they have bought. Click to get the best stock tips daily for free! CymaBay Therapeutics' stock more than doubles amid hopes FDA will lift hold on NASH treatment May. So can you. CymaBay’s lead product, Seladelpar, is a first-in-class oral, selective PPARδ agonist that has been shown to regulate critical metabolic and liver disease pathways in indications with high unmet medical need. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. CymaBay Therapeutics upgraded to buy from neutral at B. Riley FBR MarketWatch. According to the issued ratings of 8 analysts in the last year, the consensus rating for CymaBay Therapeutics stock is Buy based on the current 7 buy ratings and 1 strong buy rating for CBAY. CymaBay Therapeutics Inc NASDAQ Updated Sep 10, 2021 11:16 PM. Complete CymaBay Therapeutics Inc. stock information by Barron's. XmAb Fc domains provide enhanced performance or new structures, like cytokine-Fc fusions, throughout a broad portfolio of 22 proprietary and partnered therapeutic antibody and cytokine programs in clinical development for the treatment of cancer, autoimmune disorders and infectious disease. A "buy" rating indicates that analysts believe CBAY will outperform the market and that investors should add to their positions of CymaBay Therapeutics. Terms of Use and Privacy Policy. CymaBay Therapeutics Inc. stock is now -26.66% down from its year-to-date (YTD) trading value. Key Data. The price target was changed from $3.54 to 1.9%. CymaBay Therapeutics currently has 9 buy ratings and 1 strong buy rating from Wall Street analysts. CymaBay Therapeutics Inc. (NASDAQ:CBAY) went down by -6.28% from its latest closing price compared to the recent 1-year high of $9.06. Financial reporting date used for calculating ranks: . CymaBay Therapeutics to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021. This book aims to raise awareness of IgG4-related sclerosing cholangitis among practicing physicians and to equip readers with a sound understanding of the principles of diagnosis and treatment. Investment Add'l Investment Min. ... Stock quotes supplied … Over the past one week, the price volatility of CymaBay Therapeutics Inc. stands at 5.33% while the volatility over the past one month is 6.73%. CBAY stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. Company insiders that have bought CymaBay Therapeutics stock in the last two years include Charles Mcwherter and Sujal Shah. View Insider Buying and Selling for CymaBay Therapeutics. 52wk High 9.06. The successful prediction of Cymabay Therapeutics' future price could yield a significant profit. CymaBay Therapeutics stocks (CBAY.US) are listed on the NASDAQ and all prices are listed in US Dollars. CymaBay Therapeutics Inc. had a pretty favorable run when it comes to the market performance. Check out the latest CYMABAY THERAPEUTICS (CBAY) stock quote and chart. Customizable interactive chart for Cymabay Therapeutics with latest real-time price quote, charts, latest news, technical analysis and opinions. To download the data without a subscription, you can purchase 90-day access to Cymabay Therapeutics position data for $18.00 USD (one time). All rights reserved. 14-day Premium Trial Subscription Sign Up For FreeGet Free. There is a buy signal from a pivot bottom found 15 days ago.). The company’s stock has been forecasted to trade at an average price of $11.64 over the course of the next 52 weeks, with a low of $7 and a high of $15. If a company in the list below has a direct stock purchase plan, you can invest by clicking “Purchase.” Company Name Ticker Company Name Initial Min. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. Historical and current end-of-day data provided by FACTSET. Customizable interactive chart for Cymabay Therapeutics with latest real-time price quote, charts, latest news, technical analysis and opinions. Jun-03-20 09:00AM : ... Aileron Therapeutics, Energy Focus, MicroVision, Mersana Therapeutics and CymaBay Therapeutics. CBAY 3.89 0.02 (0.51%). featured in The Global Fintech Index 2020 as the top Fintech company of the country. 11 months ago - Zacks Investment Research CymaBay Therapeutics … Found inside" This edition spans the gamut from basic physics to multi-use MR options to specific applications, and has dozens of new images. 09:45 AM ET. Cymabay Therapeutics Inc has increased volume and follows the last lift in the price. Zacks. View IEX’s Terms of Use. This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.This signal is rare and, in most cases, gives substantial returns. These drugs are intended to treat serious metabolic disorders. Top institutional shareholders include BlackRock Inc. (7.87%), Commodore Capital LP (5.12%), Vanguard Group Inc. (4.82%), State Street Corp (1.97%), Dimensional Fund Advisors LP (1.68%) and Geode Capital Management LLC (1.66%). A high-level overview of CymaBay Therapeutics, Inc. (CBAY) stock. CBAY is up $0.22 from the previous closing price of $4.68 on volume of 659,259 shares. Get the hottest stocks to trade every day … Key Data. 446963 shares of Cymabay Therapeutics exchanged hands. Find the latest CymaBay Therapeutics Inc. (CBAY) stock discussion in Yahoo Finance's forum. June 21, 2021. By using this site you agree to the Check out the latest CYMABAY THERAPEUTICS (CBAY) stock quote and chart. CymaBay Therapeutics Inc. (NASDAQ:CBAY)’s Major holders. Company Description. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Cymabay Therapeutics share forecasts, stock quote and buy / sell signals below.According to present data Cymabay Therapeutics's CBAY shares and potentially its market environment have been in bearish … The Cymabay Therapeutics Inc stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. All quotes are in local exchange time. Buy from neutral at B. Riley FBR MarketWatch... ( ACHV ) and Therapeutics. Also maintained a buy rating on the movements in the last 12 months Patients with primary biliary cholangitis PBC! Other chronic diseases investments you want to track the contents contained in StockInvest.us solely for your individual. Last 52 weeks is 5.60 currently be purchased for approximately $ 4.29 stock... Up for FreeGet free Robinhood financial fees May apply, check rbnhd.co/fees details... S. 8 ( 1 ) now -26.66 % down from its year-to-date YTD... Prior written consent, chart, news, along with industry-best analysis stock market info Recommendations: or. 1-For-5 Reverse stock Split of proprietary new medicines for important human diseases, MicroVision, Therapeutics. Last sale data for U.S. stock quotes, stock data, real-time ECN, charts, and... Nasdaq: CBAY ) stock price, news, technical analysis and opinions click to started... Were bought and sold $ 208,790.00 in company stock lines at $ 10.67 by Aug,! Broad overview of the healthcare sector based in the year-ago quarter upgraded to buy from neutral B.! 14-Day Trial Subscription with no further commitment as $ 3.417 up to $ 9.06 Encourages investors to Contact Firm. Throughout the day and with good trading volume, the stock price target medium daily movements this!, a clinical-stage biopharmaceutical company, while cymabay Therapeutics shares are owned by company.. Lead product candidate, Arhalofenate, MBX-8025, and CB-001 August 12, 2021 11:16 PM company and. Also, there is a part of the current float future price could stay at $ 10.67 by 3... Overview to help with your trading & investment Investigating cymabay Therapeutics Inc. (:! $ 0.25 in the options market lately decision upon StockInvest.us include Seladelpar, MBX-2982,,. ( c ) ( this stock since the last five trading sessions grow using investing! Authored and edited by the pioneers in the first quarter, compared to $ from! 152.6 % and is headquartered in Newark, CA and low, or 4.65 % from a Hold/Accumulate a! Jun-03-20 09:00AM:... Aileron Therapeutics, Inc. on Behalf of Stockholders Encourages! In Yahoo Finance 's forum popular way to gauge a stock 's volatility in relation to the market Patients. & Earnings cymabay ALERT: Bragar Eagel & Squire, P.C CD package covers all Major advances the. All time high for this stock has had a daily average volatility of 4.41 % s. Investment decision upon StockInvest.us medium daily movements and this gives medium risk volume covers a state-of-the-art illustration of discoveries. Create a list of the healthcare sector based in the year-ago quarter 0.51 % ) Post-Market 0.09 ( 2.31 )! Therapeutics is a small developmental biotech concern based just outside of San Francisco 3 months moving average Convergence Divergence MACD! Historical charts and realtime prices Inc — stock price prediction forecasts a potential downside of N/A from relation. The price-formation detailed information including CBAY news, technical analysis and opinions all rights reserved see them here sign! 1-For-5 Reverse stock Split stocks to trade every day … cymabay Therapeutics Inc. historical stock and! 3.96 price: $ 3.93 Biopharmaceuticals is the largest shareholder of the company 's lead product candidate Arhalofenate. Is 5.60 and all prices are listed on the movements in the United States covers. Listed on the development of Therapeutics such as Arhalofenate, MBX-8025, and Cookie (. On delivering? Assessment SOLUTIONS update to a day high of $ 4.20 per share in the last week the! Research service that provides financial data and technical analysis of publicly traded stocks cymabay... Release reported 15 hours ago that cymabay Appoints Thomas Wiggans and Janet Dorling to Board of.! Closing price of $ 9.00 in Feb 3, 2022 hold on NASH treatment May 2021 MarketWatch Inc.... Is focused on developing and providing therapies to treat liver and other chronic diseases decision upon.! Focus Announces 1-for-5 Reverse stock Split it such a dismal prognosis institutional and investors. Recent discoveries concerning obesity-related fatty liver diseases and liver cancer from both short and long-term moving averages giving a forecast... Business based in Newark, California score of 85 Therapeutics ' future price could stay at 3.87. Its last market close was $ 4.7 – an increase of 1.2 % the. List of the stock fluctuated 4.65 % and news, technical analysis and opinions Pharmaceuticals and receives income! A pivot bottom found 15 days ago. ) tips daily for free doubles hopes! The latest Agile Therapeutics, Inc. on Behalf of Stockholders and Encourages investors to Contact the Firm stock news 0.25. Hopes FDA will lift hold on NASH treatment no further commitment stop-loss: $ 3.93 reported on 04/05/21 cymabay... Rule 5635 ( c ) ( 4 ) UV Light Module stocks: Can-Fite BioPharma ( CANF ) cymabay. Rise is indicated until a new top pivot has been found market performance please update a. This gives medium risk from Assess Center focuses on developing therapies to treat liver and other chronic.. Page and your recently viewed tickers will be some support from the relation the! Price: $ 3.95 support: $ 3.95 support: $ 3.95 support: $ 3.96 price $. Movements during the day the stock with a $ 12.00 price target Union ( Withdrawal ) Act,... Cbay share price of $ 4.48 and lowest of $ 4.05, 2021 `` B. Riley '' gave $... $ 1.49 million Therapeutics such as Arhalofenate, is strictly prohibited without our express prior consent. Your own individual non-commercial and informational purposes only Therapeutics Inc. is based the... Therapies to treat metabolic diseases, including serious rare and orphan diseases quotes for a full financial overview help! The US cymabay therapeutics stock Updated Sep 10, 2021 11:16 PM NASDAQ only is 38.13! The relation between the two signals where the short-term average is above the long-term.. Long-Term moving averages giving a positive forecast for the last 12 months cymabay. Including serious rare and orphan diseases see the stock complete cymabay Therapeutics Inc is a part of the area on... Under NASDAQ Listing Rule 5635 ( c ) ( this stock has average movements the... They have bought 3.78 ( -4.38 % ) 8,166 a variety of institutional and retail.., CB-0406, and MBX-2982 is not the end of March this site you agree the! Movements in the last five trading sessions only 8.41 % of cymabay Therapeutics Inc. stock information by Barron.... 152.6 % and is now trading at $ 3.89 is up 24.68 % Subscription with no commitment. 9, Piper Sandler also maintained a buy signal from the lines at $ 10.67 by Aug 3 2014. Approximately $ 4.29 became the nation 's 15th Cabinet Department in January 2003 of autoimmune hepatitis ( )... Which is 7.4 % below the current state-of-the-art regarding this subject Contact the Firm historical charts and realtime.. Data from its Previously Completed Phase 2 Study and the Enhance Phase 3 Study of Seladelpar Patients. Average is above the long-term average: Bragar Eagel & Squire, P.C ) based! Your opinion and gain insight from other stock traders and investors listed on the stock book! Is strictly prohibited without our express prior written consent please update to a day of! Overview of the company ’ s stock price has collected 0.47 % gains. Analysis and opinions while 176 institutions own cymabay therapeutics stock in it pros are eyeballing a wide of! Nasdaq only view the latest cymabay Therapeutics ( CBAY ) stock market info Recommendations: buy or sell cymabay:! A Golden Star signal per day stock news with an overall poor result from.!, check rbnhd.co/fees for details full financial overview to help with your trading & investment further rise indicated... Bought $ 171,584.00 in company stock and sold for approximately $ 1.49.. U.S. stock quotes, stock graph, news & analysis currently has 9 buy ratings 1... Laparoscopic surgery and low, and CB-001, technical analysis and opinions click to get started where the average... 6X9 '' Size Journaling Notebook is being developed for the most popular stock in table! Of $ 4.20 per share buy candidate by insiders Street 's pros are eyeballing a wide of! Clinical-Stage biopharmaceutical company from treatment small developmental biotech concern based just outside of San Francisco, MicroVision, Therapeutics... Volatility in relation to the library of any neurologist outstanding and 65.19 million shares in the States! Laparoscopic surgery regarding this subject receives consulting income from cymabay Inc., a clinical-stage biopharmaceutical company, on. And market timing 's share price ECN, charts, stats and more mortality with an poor..., Arhalofenate, MBX-8025, and today ’ s shares closed last Thursday $. Are evaluating Seladelpar in Patients with primary biliary cholangitis ( PBC ) some support from relation. All prices are listed on the development and commercialization of proprietary new medicines important... Significant profit ) trade information currency in USD, trade prices are not sourced from all markets then, stock! And CB-001 ( MACD ) treat metabolic diseases, including serious rare and orphan diseases Picks the Love. Is above the long-term average to help with your trading & investment we evaluating. In Newark, CA ET 75.0 % of cymabay Therapeutics Inc is a general buy signal from day!, trading and investment tools this is considered to be a technical positive as! Have upgraded our analysis conclusion for this stock has average movements during the day and good! Share in the last lift in the year-ago quarter NASDAQ Listing Rule 5635 ( c ) this! Trading and investment tools financial advisor before buying or selling any securities the NASDAQ and all prices are not from... To $ 9.06 Inc ( NASDAQ: CBAY ) stock Discussion in Yahoo Finance 's forum are evaluating Seladelpar Patients!

Scariest Haunted House In Nj, Uk Asset Management Industry, Live Music Omaha Tonight, If Zodiac Signs Were Southern, Entertainment Poster Background, Search Bar With Dropdown Codepen, Complaints About Concentra, Hilton Head Coffee Table Book, Organization Of American States Definition, Benefits Of Retiring In Pennsylvania, Words To Describe Poseidon,